Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17?
In 2017, Regeneron expects its eye drug, Eylea, to witness single-digit revenue growth on a year-over-year basis. Eylea has continued to be the company’s major revenue driver in the year.
Chimerix Falls 80% following Phase 3 Trial of Brincidofovir
Chimerix closed at $6.62, and its market-cap fell from $1.6 billion to $305 million on December 28, 2015.
The High Hope of Exelixis’s Cabometyx Label Expansion
Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.
Gilead Sciences on the Street in January: Analyst Recommendations
In December 2017, Gilead Sciences (GILD) and its subsidiary specialized in cell therapy, Kite, entered into an agreement with Cell Design Labs.
What to Expect from Exelixis in 1Q18
Analysts estimate that in 1Q18, Exelixis will generate revenue of $141.0 million compared to $120.1 million in 4Q17.
How Exelixis Is Positioned ahead of Its Q2 2018 Earnings Release
Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.
How Did Exelixis Perform in 1Q18?
In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.
Label Expansion May Boost Cabometyx’s Revenue in 2018
On January 16, Exelixis (EXEL) and Ipsen announced positive results from the CELESTIAL Phase 3 trial.
What Amgen’s Analysts Recommend in August 2017
Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”
Exelixis Stock Rises on Revenue Beat
Yesterday, Exelixis (EXEL) reported its second-quarter results after markets closed. Subsequently, its stock rose 0.99% and closed at $21.48.
Exelixis Stock Is Up despite Disappointing Clinical Trial Results
While Exelixis was down 5.9% in after-hours trading after the announcement of disappointing clinical trial results, the stock recovered the losses and closed at $21.14 yesterday, 0.81% higher than its previous close. Based on this price performance, it seems that shareholders had already priced in the trial’s failure.
Sarepta Therapeutics Stock Rose 96% in 2018
On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.
Why Clovis Oncology Stock Rose 48% in November
On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.
Why Exelixis Stock Soared 46% in November
Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29.
How Exelixis’s Cabozantinib Franchise Is Positioned in November
In the third quarter, Exelixis’s (EXEL) Cabozantinib franchise generated revenues of $162.9 million, reflecting ~69% YoY growth.
Exact Sciences: Why the Stock Price Is Soaring
On August 22, Exact Sciences (EXAS) is trading at a stock price of $62.95, which represents ~25.78% growth from the close of $50.05 on August 21.
Analyst Recommendations for Exelixis in August
In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, a 66% YoY growth.
Gauging Analysts’ Ratings for ArQule Stock in July
ArQule (ARQL) stock has risen from a low of $5.53 on July 5 to $6.86 on July 6. It closed 20.11% higher at $6.81 on July 6.
Analysts Are Mostly Positive on Exelixis in July
On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10.
Understanding Exelixis’s Valuations and Cash Flow Trend
In Q1 2018, Exelixis (EXEL) generated $71.8 million from operating activities compared to $68.85 million in Q1 2017.
Analyzing Exelixis’s Revenue Trend
Exelixis (EXEL) generated total revenues of $212.34 million in Q1 2018 compared to $80.88 million in Q1 2017.
Why Gemphire Therapeutics Stock Is Rising Today
Yesterday, Gemphire Therapeutics (GEMP) announced that its Phase 2b INDIGO-1 trial evaluating investigational first-in-class oral therapy, gemcabene, achieved its primary endpoint.
Solid Biosciences’ Stock Price Rose 46.6% on June 19
On June 19, 2018, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, the stock price hit a 52-week high of $54.84.
BMY Is Rapidly Advancing Its First-Line NSCLC Research Program
Opdivo has enabled Bristol-Myers Squibb to compete effectively with other melanoma players such as Merck (MRK), Exelixis (EXEL), and Amgen (AMGN).
Levnima Could Be Merck’s Long-Term Growth Driver
Eisai and Merck are conducting various clinical trials for the label expansion of Lenvima.
Opdivo Continues to Be Key Growth Driver for Bristol-Myers Squibb
In the first quarter, Bristol-Myers Squibb’s (BMY) Opdivo witnessed sales of ~$1.5 billion.
Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018
In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume.
Lenvima Is Expected to Boost Merck’s Oncology Portfolio in 2018
Lenvima is expected to enable Merck to compete effectively with other oncology players such as Exelixis (EXEL) and Pfizer (PFE).
How United Therapeutics Performed in 1Q18
In 1Q18, United Therapeutics (UTHR) generated revenues of $389.2 million compared to $370.5 million in 1Q17.
Cabometyx Could Be Exelixis’s Long-Term Growth Driver
In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx.
How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017
In 4Q17, Exelixis’s (EXEL) Cabometyx reported revenue of $90.4 million compared to $44.7 million in 4Q16.
Why Spark Therapeutics Stock Rose in the Week Ended March 29
On March 29, 2018, Spark Therapeutics was trading at $66.59, which represented a ~62% increase from its 52-week low of $41.06.
Pfizer’s Sutent Generated Higher Revenues in 4Q17
In the US and international markets in 4Q17, Sutent generated revenues of $96 million and $180 million, respectively.
Analyst Recommendations for Vertex Pharmaceuticals in January
Of the 27 analysts covering Vertex Pharmaceuticals in January 2018, ten have recommended a “strong buy,” while 13 have recommended a “buy.”
Analysts’ Recommendations for Regeneron
Dupilumab could be long-term growth driver In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety and efficacy of dupilumab for the treatment of individuals with severe steroid-dependent asthma. In the study, at 24 weeks, when […]
Gauging Exelixis’s High Hopes for Cotellic
On November 10, 2015, the FDA approved Exelixis’s (EXEL) Cotellic in combination with Roche Holdings’ (RHHBY) Zelboraf (vemurafenib) as a treatment option.
Inside Exelixis’s Label Expansion Collaborations for Cabozantinib
As a part of the broader lifecycle management for Cabometyx, Exelixis is exploring the drug in combination with other immune checkpoint inhibitors.
Behind Exelixis’s Cabometyx Strategy for 2018
Exelixis (EXEL) expects the FDA’s approval for Cabometyx for first-line RCC (renal cell carcinoma) to be a major revenue driver.
Reading the Expectations for Exelixis’s Net Profit Margin in 2017
In 3Q17, Exelixis (EXEL) witnessed the rapid adoption of Cabometyx, mainly driven by the company’s promotional efforts focused on community oncologists.
Behind 4 Key Novartis Money Makers (and Losers) in 3Q17
In 3Q17, Novartis’s (NVS) Gleevec generated revenues of $445 million, which was ~47% lower YoY (year-over-year) and ~12% lower QoQ (quarter-over-quarter).
Gilead Sciences on the Street: Analyst Recommendations in October
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy.”
How Is Cabometyx and Cometriq Positioned after 1H17?
In 2Q17, Exelixis’s (EXEL) Cabometyx generated revenues of ~$80.9 million compared to ~$17.6 million in 2Q16.
An Update on Novartis’s Sandostatin, Afinitor, and Exjade
In 1H17, Novartis’s (NVS) Sandostatin generated revenues of around $789 million, which reflected a ~4% decline on a year-over-year (or YoY) basis.
Analyst Recommendations for Regeneron Pharmaceuticals in August
Twenty-five analysts were analyzing Regeneron Pharmaceuticals in August 2017. Seven of them recommended a “strong buy,” and five recommended a “buy.”
Bristol-Myers Squibb’s 2Q17 Earnings: Opdivo
Bristol-Myers Squibb’s (BMY) blockbuster drug Opdivo reported revenue of $1.2 billion in 2Q17, a 42% rise compared to $840 million in 2Q16.
Inside Exelixis’s Robust Growth Strategy for Cabometyx
Exelixis is now developing a strong sales team to support the commercial launch of Cabometyx for indications like first-line RCC and second-line HCC.
Exelixis’s Tough Competition in Renal Cell Carcinoma
After the launch of Cabometyx in the US in 2Q16, Exelixis has focused its attention on promoting it to thought leaders and clinicians who have treated many RCC patients.
Behind Exelixis’s Successful Commercial Launch of Cabometyx in 2016
Launched in the US in 2Q16, Exelixis’s (EXEL) Cabometyx managed to fetch revenues of $31.2 million and $44.7 million in 3Q16 and 4Q16, respectively.
IBB Begins the Last Week of 2015 on a Negative Note
The iShares Nasdaq Biotechnology ETF (IBB) fell by 0.75% on December 28, underperforming the broader market.
FuelCell Energy’s Outlook and Analysts’ Recommendations
Among the Wall Street analysts tracking FuelCell Energy, 67% are in the favor of a “buy,” while 33% recommend a “hold” on the stock.